| Date | Title | Description |
| 07.12.2025 | Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List | SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 12.08.2025 | ConnectiveRx Thought Leaders Share Insights on Point of Care Measurement, Drug Pricing Impact, and Future of Patient Access | ConnectiveRx
Joanne Biscardi, Kristine McGaughey, and Chris Dowd demonstrate company's deep expertise across patient support ecosystem
WHIPPANY, N.J., Aug. 12, 2025 /PRNewswire-PRWeb/ -- ConnectiveRx, a leading provider of technology-enable... |
| 03.03.2025 | Nuvation Bio: Up To $250 Million In Non-Dilutive Financings Secured | Nuvation Bio, a global biopharmaceutical company addressing some of the greatest unmet needs in oncology, today announced non-dilutive financings of up to $250 million with Sagard Healthcare Partners. The deal features a royalty interest fi... |
| 03.01.2025 | Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration | SAN FRANCISCO and SUZHOU, China, Jan. 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 20.12.2024 | Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration | SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 02.08.2024 | Singapore to merge EDBI, SEEDS Capital to form SG Growth Capital | Singapore will merge two state-backed investment agencies, EDBI and SEEDS Capital, to form a new entity next year, according to an announcement on Friday.
EDBI, the investment arm of Singapore’s Economic Development Board (EDB), and SEEDS C... |
| 02.06.2024 | Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 02.06.2024 | Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting | SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 20.01.2022 | Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors | NEW YORK, Jan. 20, 2022 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that th... |
| 15.12.2021 | Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme | NEW YORK, Dec. 15, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that th... |
| 13.12.2021 | Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer | NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that th... |
| 08.12.2021 | Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer | NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the... |
| 11.11.2021 | Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update | NEW YORK, Nov. 10, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financia... |
| 10.11.2021 | Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update | NEW YORK, Nov. 10, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financia... |
| 12.08.2021 | Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update | NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financia... |
| 17.05.2021 | Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update | NEW YORK, May 17, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its finan... |
| 11.03.2021 | Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update | NEW YORK, March 11, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its fin... |
| 10.03.2021 | NUVATION BIO INC.
Panacea Acquisition : Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company | Combined company renamed Nuvation Bio Inc., will be listed on the New York Stock Exchange under ticker symbol 'NUVB'
Strong cash position of approximately $830 million includes approximately $646 million held in Panacea's trust account and ... |
| 10.02.2021 | Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company | |
| 28.10.2020 | Ally Bridge Portfolio News – Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development | NEW YORK – – October 21, 2020 – Nuvation Bio, Inc., a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology, and Panacea ... |
| 26.10.2020 | Nuvation Bio Expands Executive Team with Appointment of Healthcare Investment Banking Leader Jennifer Fox as Chief Financial Officer | |
| 20.02.2020 | The evolution of New York City as a bioinnovation hub highlighted in new report | Three years ago, in its inaugural report on the venture capital landscape, New York City Health Business Leaders calculated that 79 startups and growth stage companies received $703 million in 2017. To put that in a national perspective, St... |
| 31.10.2019 | EDBI, Pavilion Capital backed US-based Nuvation Bio’s $275m Series A | Premium
Nuvation Bio, a US-based oncology company, has closed $275 million in a Series A funding round led by Omega Funds, a global life sciences investment firm.
Continue reading this story with a subscription to DealStreetAsia.
Subscribe
... |
| 28.10.2019 | Oncology Start-Up Nuvation Bio Closes $275 Million Series A Financing Led by Omega Funds | Nuvation Bio, Inc., a stealth biotechnology company developing proprietary therapies focused on oncology, announces the closing of $275 million in an oversubscribed Series A financing. The round was led, structured and syndicated by Omega F... |
| 28.10.2019 | Nuvation Bio Raises $275M in Series A Financing | Nuvation Bio, Inc., a NYC-based stealth biotechnology company developing proprietary therapies focused on oncology, closed a $275 million Series A financing.
The round was led, structured and syndicated by Omega Funds and included participa... |
| 28.10.2019 | Biotech startup Nuvation Bio emerges from stealth with $275M in Series A funding for the development of next generation therapies with focus on oncology | Nuvation Bio, a biotech startup developing proprietary therapies focused on oncology, has emerged from stealth with $275 million in Series A financing. The round was led by Omega Funds, with participation from leading biotechnology investor... |
| - | Panacea Acquisition : Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company | Combined company renamed Nuvation Bio Inc., will be listed on the New York Stock Exchange under ticker symbol 'NUVB'
Strong cash position of approximately $830 million includes approximately $646 million held in Panacea's trust account and ... |
| - | The evolution of New York City as a bioinnovation hub highlighted in new report | Three years ago, in its inaugural report on the venture capital landscape, New York City Health Business Leaders calculated that 79 startups and growth stage companies received $703 million in 2017. To put that in a national perspective, St... |
| - | Nuvation Bio Granted Orphan Drug Designation for NUV-422 for the Treatment of Patients with Malignant Gliomas | NEW YORK, March 11, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that t... |
| - | Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update | NEW YORK, March 11, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its fin... |
